ABSTRACT
Objective To approach curative effect of using DLI +IL-2 as immunobiotherapy after Mixed-HSCT in acute myelogenous leukemia.MethodAfter times of chemotherapy,8 cases of patients with acute myelogenous leukemia received Mixed-HSCT,then were treated with DLI +IL-2 for 2-7 times.Observed clinical effect for 1 to 5 years.Result DFS in 8 cases of patients with acute myelogenous leukemia received Mixed-HSCT and treated with DLI +IL-2 for 2-7 times were 62.5%.There were no GVHD.Conclusion Immuno-biotherapy with DLI +IL-2 after Mixed-HSCT in patients of acute myelogenous leukemia may be a method to increase DFS efficiently.
ABSTRACT
<p><b>OBJECTIVE</b>To study whether As(2)O(3) has an apoptotic effect on human solid tumor cells, and the possible cellular and molecular mechanisms of this treatment using human esophageal squamous carcinoma cells (EC8712) as a model.</p><p><b>METHODS</b>DNA microarray, biochemical and cytological analyses were used.</p><p><b>RESULTS</b>The growth and survival of EC8712 cells were markedly inhibited by As(2)O(3) treatment at a concentration of 1, 2 and 4 micromol/L. EC8712 cells were obviously arrested at G2/M phase with As(2)O(3) treatment and apoptosis induced at micromolar As(2)O(3) concentrations, as shown by morphology, histogram related nuclear DNA contents, and DNA gel electrophoresis. As(2)O(3) activated caspase-3, which might be involved in the process of As(2)O(3), induced apoptosis in EC8712 cells.</p><p><b>CONCLUSIONS</b>As(2)O(3) changes the expression of many genes at transcription level. The regulation of expression of many genes might be involved in the process of As(2)O(3) inducing apoptosis. These results suggest that As(2)O(3) can be clinically useful for solid tumor treatment.</p>
Subject(s)
Humans , Apoptosis , Arsenicals , Pharmacology , Carcinoma, Squamous Cell , Drug Therapy , Genetics , Pathology , Cell Adhesion , Cell Division , DNA Fragmentation , Dose-Response Relationship, Drug , Esophageal Neoplasms , Drug Therapy , Genetics , Pathology , Gene Expression Regulation, Neoplastic , Microscopy, Electron , Oxides , Pharmacology , Tumor Cells, CulturedABSTRACT
Objective To explore the dynamic changes of CD34 + cells and T lymphocyte subsets and best time of harvesting peripheral blood stem cell when G-CSF was used for peripheral blood stem cell mobilization in donors and patients. Methods A total of 12 donors and 16 patients who received chemotherapy for 7 d were injected G-CSF of 300 ?g/d to mobilize peripheral blood stem cells for 5 d and flow cytometry were used to detect the changes of CD34 + cells and T lymphocyte subsets everyday for 5 d. Results ① Before G-CSF treatment, there were obvious differences in bone marrow CD34 + cells between patients and donors (P
ABSTRACT
Objective To approach the dynamic changes of CD~+_ 34 cells and T lymphocyte subsets and best time of peripheral blood stem cell harvest when using rHuG-CSF for peripheral blood stem cell mobilization in donors and patients.Methods From 2001 to 2002 12 donors and 16 patients in Lanzhou General Hospital who received chemotherapy 7 days ago were injected rHuG-CSF 300 ?g/d for mobilization peripheral blood stem cells,and flow cytometry were used to detect the changes of CD~+_ 34 cells and T lymphocyte subsets for 5 days.Results (1)Before using rHuG-CSF,there was obvious difference between patients and donors in bone marrow CD~+_ 34 cells(P